Clinical trials: Stage I Skin Cancer
Inflammatory Breast Cancer, Stage II Breast Cancer
Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer
Drugs used in chemotherapy, such as doxorubicin and cyclophosphamide, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Inflammatory Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
- Trial name
- NCT00049114
- Testing
- doxorubicin hydrochloride, cyclophosphamide, tipifarnib
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Cancer, Lymphoma
A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma
This is a Phase I/II, dose-escalation and expansion study of NUC-7738 administered by intravenous infusion as a monotherapy and in combination with pembrolizumab.
- Conditions
- Advanced Cancer, Lymphoma, Solid Tumor, Melanoma
- Trial name
- NCT03829254
- Testing
- NUC-7738, Pembrolizumab
- Where
- 9 sites in United Kingdom
- Volunteers
- 135 people
- Sponsor
- NuCana plc
Metastatic/Recurrent Breast Cancer
Pharmacokinetic Study of Tesmilifene (YMB1002) Plus Epirubicin and Cyclophosphamide in Metastatic Breast Cancer
This is a Phase I, multi-centre, open-label, cross-over pharmacokinetic study designed to investigate whether the co-administration of a fixed dose of tesmilifene alters the plasma pharmacokinetics of a standard regimen of…
- Trial name
- NCT00364754
- Testing
- Tesmilifene (YMB 1002)
- Where
- 10 sites in Georgia, Russia and 1 more
- Volunteers
- 28 people
- Sponsor
- YM BioSciences
Breast Cancer, Colorectal Cancer
Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer
This research study is for individuals who have advanced breast, colon, pancreatic, ovarian or bladder cancer. Celldex Therapeutics, Inc.
- Conditions
- Breast Cancer, Colorectal Cancer, Pancreatic Cancer, Bladder Cancer
- Trial name
- CDX1307-02 (NCT00648102)
- Testing
- CDX-1307
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Celldex Therapeutics
Breast Cancer
Quality of Life in Postmenopausal Women Who Are Receiving Either Exemestane or Anastrozole With or Without Celecoxib for Stage I, Stage II, or Stage IIIA Primary Breast Cancer
RATIONALE: Quality-of-life assessment in postmenopausal women who are receiving hormone therapy for breast cancer may help to determine the effects of treatment on these patients and may improve the quality of life for future…
- Trial name
- NCT00090974
- Testing
- quality-of-life assessment
- Where
- 224 sites in United States
- Sponsor
- Eastern Cooperative Oncology Group
Breast Cancer
Strength and Range of Motion in Women Undergoing Surgery for Breast Cancer
RATIONALE: Gathering information about strength and range of motion over time from women undergoing surgery for breast cancer may help doctors learn more about recovery from surgery and on-going care.
- Trial name
- NCT00489125
- Testing
- physiologic testing
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Wake Forest University Health Sciences
Breast Cancer
Letrozole in Treating Breast Cancer in Postmenopausal Women With Stage I, II, or III Breast Cancer Previously Treated With Tamoxifen (GIM4)
RATIONALE: Estrogen can cause the growth of breast cancer cells. Letrozole may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- GIM4 (NCT01064635)
- Testing
- Letrozole
- Where
- Italy
- Volunteers
- 2,056 people
- Sponsor
- IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Breast Cancer, Estrogen Receptor-positive Breast Cancer
COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer
This study is designed to assess the safety and clinical activity of tamoxifen and the COX inhibitor, aspirin, given in combination with standard AC-T chemotherapy (doxorubicin, cyclophosphamide, and paclitaxel) for the treatment…
- Trial name
- Breast 51 (NCT04038489)
- Testing
- Aspirin, Tamoxifen Pill, Doxorubicin
- Where
- United States
- Sponsor
- University of Virginia
Breast Cancer, Cancer Survivor
Study of Support Groups for African-American Breast Cancer Survivors
RATIONALE: A study that evaluates successful Los Angeles-based, peer-led African American breast cancer survivor support groups may help in developing a guide on how to organize and maintain breast cancer support groups.
- Trial name
- NCT00949871
- Testing
- communication analysis, questionnaire administration, psychosocial assessment and care
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- City of Hope Medical Center
Breast Cancer Stage 0, Breast Cancer Stage I
Optimizing Surgical Decisions in Young Adults With Breast Cancer
The goal of this study is to understand and improve the breast surgical decision-making process for young women newly diagnosed with breast cancer.
- Conditions
- Breast Cancer Stage 0, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
- Trial name
- CONSYDER (NCT06275126)
- Testing
- CONSYDER decision aid
- Where
- 4 sites in United States
- Volunteers
- 800 people
- Sponsor
- Weill Medical College of Cornell University
Melanoma
Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma
The purpose of this research study is to determine the safety of using the study drugs bevacizumab and ipilimumab together, and the doses in combination which can be given to people safely.
- Trial name
- NCT00790010
- Testing
- Bevacizumab Plus Ipilimumab Cohort 1, Bevacizumab Plus Ipilimumab Cohort 2, Bevacizumab Plus Ipilimumab Cohort 3
- Where
- 3 sites in United States
- Volunteers
- 46 people
- Sponsor
- Dana-Farber Cancer Institute
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer and HR+/HER2- Metastatic Breast Cancer
This phase II trial studies the side effects and best dose of ivermectin in combination with balstilimab or pembrolizumab and to see how well they they work in shrinking tumors in patients with triple negative breast cancer and…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, HR+ / HER2- Advanced Breast Cancer
- Trial name
- NCT05318469
- Testing
- Ivermectin, Balstilmab, Pembrolizumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Yuan Yuan
Breast Cancer
Study of Biweekly Capecitabine Dosing With Bevacizumab for the Treatment of Metastatic Breast Cancer Based Upon the Norton-Simon Mathematical Model
The purpose of this study is to find out what effects (both good and bad) that capecitabine has on you and your breast cancer when given in a novel schedule in combination with the antibody therapy, bevacizumab.
- Trial name
- NCT00468585
- Testing
- Capecitabine, Bevacizumab
- Where
- 5 sites in United States
- Volunteers
- 62 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
Simvastatin and Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ or Invasive Breast Cancer
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of simvastatin and anastrozole may stop cancer from forming, growing, or coming back in patients with invasive…
- Trial name
- NCT00354640
- Testing
- anastrozole, simvastatin, pharmacological study
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Cancer Exercise: Evaluation of a Mobile App in Breast Cancer Survivors
This study will examine whether a mobile app increases exercise levels in breast cancer survivors after treatments, reduces fatigue, and improves physical functions.
- Trial name
- NCT06791018
- Testing
- Exercise
- Where
- Canada
- Volunteers
- 132 people
- Sponsor
- University of Alberta
Breast Cancer
Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using triptorelin, exemestane, and tamoxifen may fight breast cancer by blocking the use of estrogen.
- Trial name
- TEXT (NCT00066703)
- Testing
- exemestane, tamoxifen, triptorelin
- Where
- 228 sites in United States, Australia and 15 more
- Volunteers
- 2,672 people
- Sponsor
- ETOP IBCSG Partners Foundation
Cancer
Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy
RATIONALE: Vaccines may help the body build an effective immune response to kill cytomegalovirus infections. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients who have…
- Trial name
- NCT00509691
- Testing
- cytomegalovirus pp65-specific cytotoxic T lymphocytes, polymerase chain reaction, diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Louisville
Metastatic Melanoma Stage IV
A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma
A prospective, open-label, multi-center, Phase I/II study of L19IL2 in combination with Dacarbazine in patients with metastatic melanoma.
- Trial name
- NCT02076646
- Testing
- L19IL2 - Ph I, L19IL2 at RD - Ph II, DTIC
- Where
- 2 sites in Germany, Italy
- Volunteers
- 96 people
- Sponsor
- Philogen S.p.A.
Breast Adenocarcinoma, Estrogen Receptor Positive
PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer
This phase I/II trial studies the side effects and the best dose of triciribine phosphate when given together with paclitaxel, doxorubicin hydrochloride, and cyclophosphamide and to see how well they work in treating patients…
- Conditions
- Breast Adenocarcinoma, Estrogen Receptor Positive, HER2/Neu Negative, Recurrent Breast Carcinoma
- Trial name
- NCT01697293
- Testing
- Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- Prescient Therapeutics, Ltd.
Metastatic Breast Cancer
Safety Study of Radiation and CP-675,206 Infusion for Breast Cancer Patients
The purpose of this study is to determine the maximum dose of CP-675,206 when given in combination with radiation. Patients will be given local radiation to one tumor site and an intravenous infusion of CP-675,206.
- Trial name
- NCT01334099
- Testing
- CP-675,206, External local radiation therapy
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- University Health Network, Toronto